Cancer glossary
Luminal A vs luminal B breast cancer: what the difference is
What luminal A or B means on your report: the ER, PR, HER2 and Ki-67 cutoffs used in Russian guidelines, and how the subtype shapes treatment choices.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
Luminal subtypes are hormone-sensitive breast cancers that have estrogen receptors. Luminal A grows more slowly and relies mainly on hormone therapy; luminal B divides more actively or carries HER2, and its treatment is usually more intensive.
How it appears in your report
- ‘Surrogate molecular subtype: luminal A’ — a conclusion by the pathologist or oncologist.
- ‘ER Allred 8, PR 2%, HER2 0, Ki-67 12%’ — no subtype stated, but it can be worked out: here the low PR makes the tumor luminal B.
- ‘Luminal B, HER2-positive’ — a hormone-sensitive tumor with excess HER2.
‘Surrogate’ means the subtype was assigned from IHC markers rather than from a genetic analysis of the tumor.
What it means
Criteria from the RUSSCO practice guidelines:
| Subtype | Features |
|---|---|
| Luminal A | ER+, HER2−, Ki-67 ≤ 20%, PR ≥ 20% — all of these |
| Luminal B, HER2-negative | ER+, HER2−, and either Ki-67 ≥ 30% or PR < 20% |
| Luminal B, HER2-positive | ER+, HER2+, any Ki-67 and PR |
For Ki-67 values between 20% and 30%, RUSSCO recommends weighing stage, grade and the lab’s experience. Tumors without hormone receptors are not luminal: these are the HER2-positive non-luminal and triple-negative subtypes.
Does it affect treatment
Yes, the subtype is one of the main pillars of the plan. For both luminal subtypes, hormone therapy is discussed. In HER2-negative luminal B, chemotherapy comes up more often; in HER2-positive luminal B, anti-HER2 drugs are added. Your doctor decides what you actually need based on subtype and stage together.
Questions to ask your doctor
- What is my subtype, and which markers was it based on?
- If my Ki-67 is between 20% and 30%, what else is taken into account?
- Do I need chemotherapy, or is hormone therapy enough?
More in the articles on IHC and on hormone therapy for breast cancer. I can help you make sense of your subtype in a new-diagnosis consultation.
Sources
- Практические рекомендации по лекарственному лечению рака молочной железы — RUSSCO, 2023
- Breast Cancer Biomarker Tests — National Cancer Institute, 2025
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group — JNCI, 2021
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
